Proton therapy developer Mevion Medical Systems has won a contract with the Centre Hospitalier Universitaire Vaudois in Lausanne for its Mevion S250 proton therapy system.
The deal represents the first sale of the device in Europe, according to Mevion. The system was purchased via a partnership between the facility and Swiss firm Innovative Care. Construction will begin in the first quarter of 2016, and the first patient will be treated in 2017, the company said.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
